ArticleFrontiers in endocrinology2025
Epidemiological study of thyroid cancer at global, regional, and national levels from 1990 to 2021: an analysis derived from the Global Burden of Disease Study 2021.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Recombinant human thyrotropin reducing insulin resistance in patients with differentiated thyroid cancer.Journal of the Endocrine Society · 2026Article
- Psychological Assessment of Parenting Stress and Emotional Support: A Moderated Mediation Model of Psychological Distress and Well-Being Among Childbearing-Age Women with Thyroid Cancer.Behavioral sciences (Basel, Switzerland) · 2026Article
- Targeting Sirtuins in Thyroid Cancer: Mechanisms, Drug Development, and Emerging Roles in Tumor Immunity and Ferroptosis.Cancers · 2026Review
- Early Detection of Transient Hypoparathyroidism After Total Thyroidectomy: A Single-Center Preliminary Study.Medicina (Kaunas, Lithuania) · 2026Article
- New Insights into the Development of Papillary Thyroid Cancer: The Roles of miR-1179 and ELF3.Cells · 2026Article
- Exploratory Statistical Analyses of Clinical and Biochemical Factors for Differentiated Thyroid Cancer from a Romanian Cohort.Cancers · 2026Article
- Thirty years of NCI thyroid cancer research investment (1996-2025): a longitudinal portfolio analysis of funding trends, molecular target emphasis and thematic evolution.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: A comprehensive evaluation of the disease burden is essential for identifying effective strategies to address thyroid cancer. This study delineates the long-term global trends in thyroid cancer and its epidemiological characteristics. Methods: Data on thyroid cancer from the Global Burden of Disease 2021 were utilized. The burden of thyroid cancer was assessed through measures of incidence, mortality, disability-adjusted life years (DALYs), and the socio-demographic index (SDI). Additionally, a global risk attribution analysis was conducted, and the Bayesian age-period-cohort (BAPC) model was employed to project the future global burden of thyroid cancer. Results: In 2021, there were an estimated 2 million (95% UI: 1.8, 2.2) cases of thyroid cancer worldwide, with an age-standardized prevalence rate of 23.1 (95% UI: 20.7, 25.6) per 100,000 individuals, reflecting a 55% increase since 1990. The global mortality from thyroid cancer in 2021 was 44,800 (95% UI: 39,900, 48,500), with an age-standardized rate of 0.5 per 100,000 people (95% UI: 0.5, 0.6), marking a 7% decrease since 1990. In the same year, the global total number of DALYs attributable to thyroid cancer was 1,246.5 thousand (95% UI: 1,094.4, 1,375.9), with an age-standardized rate of 14.6 per 100,000 population (95% UI: 12.8, 16.1), representing a 4.2% reduction compared to 1990. Conclusion: Over the past three decades, the age-standardized prevalence rate of thyroid cancer has increased, while the age-standardized mortality rate and DALY rate have decreased. Significant variations in prevalence, morbidity, and mortality exist across regions and countries. SDI plays a crucial role in the development of thyroid cancer, which is expected to remain a major public health challenge in the future.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.